Viking is developing what might be a game-changing medication in the segment.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Canadian oil producer Imperial Oil posted a rise in first-quarter profit on Friday, driven primarily by stronger margins in ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

Alphabet's Google will face a trial in September on antitrust enforcers' proposals to make it sell off part of its ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Euroclear plans to seize and redistribute about 3 billion euros ($3.4 billion) of Russia's funds that are frozen at the ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...